vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Essex Property Trust (ESS). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $479.6M, roughly 2.0× Essex Property Trust). Essex Property Trust runs the higher net margin — 17.9% vs 0.7%, a 17.2% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 5.5%). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 6.0%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.

ASTH vs ESS — Head-to-Head

Bigger by revenue
ASTH
ASTH
2.0× larger
ASTH
$950.5M
$479.6M
ESS
Growing faster (revenue YoY)
ASTH
ASTH
+37.4% gap
ASTH
42.9%
5.5%
ESS
Higher net margin
ESS
ESS
17.2% more per $
ESS
17.9%
0.7%
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
6.0%
ESS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
ESS
ESS
Revenue
$950.5M
$479.6M
Net Profit
$6.6M
$85.7M
Gross Margin
70.0%
Operating Margin
1.9%
31.7%
Net Margin
0.7%
17.9%
Revenue YoY
42.9%
5.5%
Net Profit YoY
184.4%
-71.6%
EPS (diluted)
$0.12
$1.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
ESS
ESS
Q4 25
$950.5M
$479.6M
Q3 25
$956.0M
$473.3M
Q2 25
$654.8M
$469.8M
Q1 25
$620.4M
$464.6M
Q4 24
$665.2M
$454.5M
Q3 24
$478.7M
$450.7M
Q2 24
$486.3M
$442.4M
Q1 24
$404.4M
$426.9M
Net Profit
ASTH
ASTH
ESS
ESS
Q4 25
$6.6M
$85.7M
Q3 25
$373.0K
$172.7M
Q2 25
$9.4M
$231.5M
Q1 25
$6.7M
$212.8M
Q4 24
$-7.8M
$301.7M
Q3 24
$16.1M
$125.5M
Q2 24
$19.2M
$99.0M
Q1 24
$14.8M
$285.1M
Gross Margin
ASTH
ASTH
ESS
ESS
Q4 25
70.0%
Q3 25
69.2%
Q2 25
70.7%
Q1 25
69.6%
Q4 24
70.0%
Q3 24
69.5%
Q2 24
70.8%
Q1 24
69.7%
Operating Margin
ASTH
ASTH
ESS
ESS
Q4 25
1.9%
31.7%
Q3 25
2.0%
44.5%
Q2 25
3.1%
59.5%
Q1 25
3.3%
55.3%
Q4 24
0.1%
67.0%
Q3 24
5.9%
28.6%
Q2 24
6.2%
31.1%
Q1 24
7.5%
31.0%
Net Margin
ASTH
ASTH
ESS
ESS
Q4 25
0.7%
17.9%
Q3 25
0.0%
36.5%
Q2 25
1.4%
49.3%
Q1 25
1.1%
45.8%
Q4 24
-1.2%
66.4%
Q3 24
3.4%
27.8%
Q2 24
3.9%
22.4%
Q1 24
3.7%
66.8%
EPS (diluted)
ASTH
ASTH
ESS
ESS
Q4 25
$0.12
$1.24
Q3 25
$0.01
$2.56
Q2 25
$0.19
$3.44
Q1 25
$0.14
$3.16
Q4 24
$-0.14
$4.00
Q3 24
$0.33
$1.84
Q2 24
$0.40
$1.45
Q1 24
$0.31
$4.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
ESS
ESS
Cash + ST InvestmentsLiquidity on hand
$429.5M
$76.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$5.5B
Total Assets
$2.2B
$13.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
ESS
ESS
Q4 25
$429.5M
$76.2M
Q3 25
$463.4M
$66.0M
Q2 25
$342.1M
$58.7M
Q1 25
$260.9M
$98.7M
Q4 24
$290.8M
$66.8M
Q3 24
$350.3M
$71.3M
Q2 24
$327.7M
$55.2M
Q1 24
$337.3M
$499.0M
Total Debt
ASTH
ASTH
ESS
ESS
Q4 25
Q3 25
$6.4B
Q2 25
$6.4B
Q1 25
$6.8B
Q4 24
Q3 24
$6.4B
Q2 24
$6.2B
Q1 24
$6.6B
Stockholders' Equity
ASTH
ASTH
ESS
ESS
Q4 25
$779.3M
$5.5B
Q3 25
$775.5M
$5.6B
Q2 25
$765.5M
$5.6B
Q1 25
$745.4M
$5.6B
Q4 24
$712.7M
$5.5B
Q3 24
$704.6M
$5.4B
Q2 24
$678.9M
$5.5B
Q1 24
$653.5M
$5.5B
Total Assets
ASTH
ASTH
ESS
ESS
Q4 25
$2.2B
$13.2B
Q3 25
$2.2B
$13.2B
Q2 25
$1.4B
$13.2B
Q1 25
$1.3B
$13.2B
Q4 24
$1.4B
$12.9B
Q3 24
$1.3B
$12.6B
Q2 24
$1.3B
$12.5B
Q1 24
$1.2B
$12.9B
Debt / Equity
ASTH
ASTH
ESS
ESS
Q4 25
Q3 25
1.15×
Q2 25
1.14×
Q1 25
1.22×
Q4 24
Q3 24
1.18×
Q2 24
1.13×
Q1 24
1.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
ESS
ESS
Operating Cash FlowLast quarter
$-2.9M
$1.1B
Free Cash FlowOCF − Capex
$-6.0M
FCF MarginFCF / Revenue
-0.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
-0.44×
12.53×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
ESS
ESS
Q4 25
$-2.9M
$1.1B
Q3 25
$10.0M
$342.6M
Q2 25
$90.9M
$216.1M
Q1 25
$16.6M
$281.5M
Q4 24
$-10.9M
$1.1B
Q3 24
$34.0M
$316.2M
Q2 24
$23.2M
$218.9M
Q1 24
$6.0M
$314.9M
Free Cash Flow
ASTH
ASTH
ESS
ESS
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
ESS
ESS
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
ESS
ESS
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
ESS
ESS
Q4 25
-0.44×
12.53×
Q3 25
26.69×
1.98×
Q2 25
9.65×
0.93×
Q1 25
2.48×
1.32×
Q4 24
3.54×
Q3 24
2.11×
2.52×
Q2 24
1.21×
2.21×
Q1 24
0.40×
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

ESS
ESS

Segment breakdown not available.

Related Comparisons